Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neoadjuvant Multimodality Treatment in T4GC

Surgery and nonsurgery therapies working singly and together

Publish date:: June 30, 2015

Treatment with neoadjuvant multimodality treatment (MMT) is increasing and is associated with prolonged survival, according to a study of 4,369 patients with T4 gastric cancer (T4GC). Researchers’ findings included:

• Surgery alone and chemotherapy with or without radiotherapy without resection are both associated with poor outcomes.

• From 1998 to 2011, only 15% of patients received MMT.

• Treatment with MMT increased during that period and was utilized in 25% of patients by 2006.

• Median overall survival (OS) was longest (19.2 months) in patients receiving MMT.

• Median OS was shorter in patients receiving surgical resection (9.0 months) or nonsurgical therapy (8.3 months).

• Median OS was longer in patients receiving neoadjuvant (27.8 months) vs adjuvant therapy (16.6 months).

Citation: Lowenfeld L, Datta J, Lewis RS Jr, et al. Multimodality treatment of T4 gastric cancer in the United States: utilization trends and impact on survival. [Published online ahead of print June 23, 2015]. Ann Surg Oncol. doi: 10.1245/s10434-015-4677-y.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,